论文部分内容阅读
目的观察重组人干扰素α-2b肌内注射联合氧气驱动雾化吸入辅助治疗毛细支气管炎临床疗效。方法选择2014年10月至2015年2月天津市蓟县人民医院收治的毛细支气管炎患儿120例,其中男性68例,女性52例,年龄5~13个月。随机分成对照组、治疗组。治疗组在常规给予抗炎、止咳、平喘治疗基础上加用重组人干扰素α-2b肌内注射及氧气驱动雾化吸入治疗。结果治疗组患儿咳嗽、喘息症状减轻及肺部喘鸣音消失时间均较对照组缩短。结论重组人干扰素α-2b辅助治疗毛细支气管炎疗效显著,值得临床推广。
Objective To observe the clinical efficacy of intramuscular injection of recombinant human interferon α-2b combined with oxygen-driven atomization inhalation in the treatment of bronchiolitis. Methods From October 2014 to February 2015, 120 children with bronchiolitis were admitted to Tianjin Jixian People’s Hospital, including 68 males and 52 females, aged from 5 to 13 months. Randomly divided into control group, treatment group. The treatment group was treated with intramuscular injection of recombinant human interferon alpha-2b and aerosol-driven inhalation therapy on the basis of conventional anti-inflammatory, cough-relieving and antiasthmatic treatment. Results The treatment group had shorter cough and wheezing symptoms than the control group. Conclusions Recombinant human interferon α-2b adjuvant therapy for bronchiolitis has significant curative effect and is worthy of clinical promotion.